Compare WILC & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WILC | PEPG |
|---|---|---|
| Founded | 1994 | 2018 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 347.3M | 113.3M |
| IPO Year | 2001 | 2022 |
| Metric | WILC | PEPG |
|---|---|---|
| Price | $27.95 | $1.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $11.17 |
| AVG Volume (30 Days) | 1.2K | ★ 2.3M |
| Earning Date | 05-18-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.97% | N/A |
| EPS Growth | N/A | ★ 25.61 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.45 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.22 | $1.01 |
| 52 Week High | $31.16 | $7.80 |
| Indicator | WILC | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 56.27 | 21.57 |
| Support Level | $25.97 | $1.17 |
| Resistance Level | $28.66 | $5.46 |
| Average True Range (ATR) | 0.66 | 0.28 |
| MACD | 0.36 | -0.06 |
| Stochastic Oscillator | 83.38 | 10.00 |
G. Willi-Food International Ltd is an Israeli-based company specializing in high-quality, great-tasting kosher food products. The company is engaged, directly and through subsidiaries, in the design, import, marketing and distribution of a variety of over 650 food products. The principal product line includes Canned Vegetables and Pickles, Canned Fish, Canned Fruit, Edible Oils, Dairy and Dairy Substitute Products, Cereals, rice and pastas, and Other Products. The company has one reportable segment: Import- export, marketing and distribution of food products. The majority of the company's revenue is derived from the sale of Dairy and Dairy Substitute Products.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.